Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study - Takeaways - MDSpire

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study

  • By

  • Shuai Zhao

  • Lu-Yao Xu

  • Ping Chen

  • Su Zhang

  • Kai-Li Mao

  • July 7, 2026

  • 0 min

Share

  • 1

    Aromatase inhibitors are used in breast cancer treatment but are associated with tendon disorders that are often underestimated.

  • 2

    The study analyzed tendon disorder reports linked to aromatase inhibitors from the FDA’s FAERS database from 2004 to 2024.

  • 3

    Twelve positive signals for tendon disorders were identified, with trigger finger and tenosynovitis stenosans showing significant associations.

  • 4

    Letrozole had the earliest onset of tendon disorders at 74 days, while exemestane had the latest onset at 243.5 days.

  • 5

    The study provides insights into the risk trends and varying degrees of tendon toxicity associated with third-generation aromatase inhibitors.

Original Source(s)

Unveiling the tendon toxicity spectrum of anastrozole, letrozole, and exemestane: a real-world pharmacovigilance study

  • by Shuai Zhao, Lu-Yao Xu, Ping Chen, Su Zhang, Kai-Li Mao

  • July 7, 2026

Related Content

Primary classical Hodgkin lymphoma of breast presenting as recurrent breast abscess in a non-lactating woman: a case report and literature review

Detection of cancer recurrence from Thai-English electronic medical records using sentence embeddings

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases